| Literature DB >> 21783379 |
Judith Maresch1, Sebastian F Schoppmann, Christiane M R Thallinger, Christoph C Zielinski, Michael Hejna.
Abstract
Discovery of the over-expression of Her-2/neu or the amplification of its regulatory gene in stomach and esophageal cancer has resulted in targeted treatment directed at this protein. The fact itself and its consequences have been the topic of an abundance of studies and clinical trials. In the present report we review the current state of the art as regards diagnosis of the over-expression and amplification of Her-2/neu, its inhibition as a new therapeutic concept, treatment toxicity, and the development of resistance to Her-2/neu as a limiting factor in stomach and esophageal adenocarcinoma.Entities:
Mesh：
Substances：
Year: 2011 PMID： 21783379 DOI： 10.1016/j.critrevonc.2011.06.003
Source DB: PubMed Journal: Crit Rev Oncol Hematol ISSN： 1040-8428 Impact factor: 6.312